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Abstract
Background: Traditional systemic chemotherapy does not provide survival benefits in patients with hepatocellular
carcinoma (HCC). Molecular targeted therapy shows promise for HCC treatment, however, the duration of
effectiveness for targeted therapies is finite and combination therapies offer the potential for improved
effectiveness.
Methods: Sorafenib, a multikinase inhibitor, and YC-1, a soluble guanylyl cyclase (sGC) activator, were tested in HCC
by proliferation assay, cell cycle analysis and western blot in vitro and orthotopic and ectopic HCC models in vivo.
Results: In vitro, combination of sorafenib and YC-1 synergistically inhibited proliferation and colony formation of
HepG2, BEL-7402 and HCCLM3 cells. The combination also induced S cell cycle arrest and apoptosis, as observed by
activated PARP and caspase 8. Sorafenib and YC-1 respectively suppressed the expression of phosphorylated STAT3
(p-STAT3) (Y705) in a dose- and time-dependent manner. Combination of sorafenib and YC-1 significantly inhibited
the expression of p-STAT3 (Y705) (S727), p-ERK1/2, cyclin D1 and survivin and SHP-1 activity compared with
sorafenib or YC-1 used alone in all tested HCC cell lines. In vivo, sorafenib-YC-1 combination significantly suppressed
the growth of HepG2 tumor xenografts with decreased cell proliferation and increased apoptosis observed by
PCNA and PARP. Similar results were also confirmed in a HCCLM3 orthotopic model. There was a reduction in
CD31-positive blood vessels and reduced VEGF expression, which suggested a combinational effect of sorafenib
and YC-1 on angiogenesis. The reduced expression of p-STAT3, cyclin D1 and survivin was also observed with the
combination of sorafenib and YC-1.
Conclusions: Our data show that sorafenib-YC-1 combination is a novel potent therapeutic agent that can target
the STAT3 signaling pathway to inhibit HCC tumor growth.
Keywords: YC-1, Sorafenib, Hepatocellular carcinoma, STAT3
* Correspondence: Zhengl@bjmu.edu.cn; cyhswb@qq.com
2The Institute of Cardiovascular Sciences and Institute of Systems
Biomedicine, School of Basic Medical Sciences, Peking University Health
Science Center, Key Laboratory of Molecular Cardiovascular Sciences of
Education Ministry, and Key Laboratory of Cardiovascular Molecular Biology
and Regulatory Peptides of Health Ministry, Beijing 100191, People’s Republic
of China
1Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital
Medical University, Beijing 100043, People’s Republic of China
Full list of author information is available at the end of the article
© 2014 Kong et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Kong et al. Molecular Cancer 2014, 13:7
http://www.molecular-cancer.com/content/13/1/7Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon neoplasm and the third most frequent cause of
cancer death [1]. Surgery, local treatment and liver
transplantation may provide curative potential for pa-
tients with HCC, however, only 10-20% of patients are
eligible for curative therapies [2]. Furthermore, trad-
itional systemic chemotherapy does not provide survival
benefits in patients with HCC. Molecular targeted ther-
apy shows promise for HCC treatment. Sorafenib (Nexa-
var
®) is the first and only molecular targeted therapy
approved for use in HCC by the U.S. Food and Drug
Administration in 2007. Sorafenib, a multiple kinase in-
hibitor, displays a remarkable inhibition of Raf-1 and
others tyrosine kinases such as vascular endothelial
growth factor receptor 2 (VEGFR2), VEGFR3, Flt-3,
platelet derived growth factor (PDGF), and fibroblast
growth factor recptor-1 (FGFR-1) [3]. Although sorafe-
nib showed survival benefits in large randomized phase
III studies, the response rate is actually quite low [4,5].
Sorafenib also causes multiple human toxicities, includ-
ing use-limiting anorexia, GI bleeds and hand-foot syn-
drome [5]. Modulation of its actions that result in
lessening of the toxicities is a desirable goal. Conse-
quently, the duration of effectiveness for targeted therap-
ies is finite; however, combination therapies offer the
potential for improved effectiveness [6].
YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole]
is an effective anti-platelet agent that increases cGMP
levels through NO-independent activation of soluble
guanylyl cyclase (sGC) and originally developed as a
drug in the treatment of platelet-rich thrombosis, vaso-
spasm or male erectile dysfunction [7]. Currently, YC-1
is also used as an inhibitor of hypoxia-inducible factor
1α (HIF-1α) to suppress the tumor growth [8]. YC-1 ex-
hibits anti-proliferative effects against various cancer cell
lines including breast cancer [9], epithelial ovarian car-
cinoma [10], bladder transitional carcinoma [8], prostate
cancer [11], oesophageal squamous carcinoma [12], renal
carcinoma [13], lung cancer [14], leukemia [15], pancre-
atic cancer [16], and HCC [17-19]. YC-1 also exhibits
potential prospective in treatment for HCC. YC-1 in-
duced cell cycle arrest and apoptosis by activating check-
point kinases in HCC cells [18,19]. YC-1 also enhanced
chemo-sensitivity and eliminated the arsenic trioxide re-
sistance in HCC [20]. Whether the combined use of YC-
1 and sorafenib has clinical therapeutic potential for
HCC patients has not been determined.
The signal transducer and activator of transcription 3
(STAT3) has been implicated in signal transduction by dif-
ferent cytokines, growth factors and oncogenes. Activated
STAT3 plays an important role in tumorigenesis through
the upregulation of genes involved in anti-apoptosis, pro-
liferation and angiogenesis [21]. Consequently, STAT3 has
emerged as a promising target for cancer therapy, which is
pharmacologically safe and effective, and blocking STAT3
activation has the potential for treatment of HCC. Recent
findings showed that sorafenib inhibited tumor growth
through Raf-MEK-MAPK-independent pathways and
STAT3 was a major kinase-independent target of sorafenib
in HCC [22], and sorafenib inhibited growth and metasta-
sis of HCC by blocking STAT3 [23]. However, endothelial
growth factor receptor (EGFR), which could activate
STAT3, has been implicated both in the inherent and ac-
quired resistance to sorafenib [24,25]. A majority of HCC
patients do not respond to sorafenib, and most if not all pa-
tients who initially respond to sorafenib, subsequently be-
come refractory and develop tumor progression after a few
months of sorafenib therapy [26]. Therefore, an approach
that improves therapeutic efficacy is urgently needed. Sev-
eral preclinical studies have revealed the apoptosis-
enhancing effects of sorafenib on both hematological and
solid tumor cells. YC-1 was also reported to inhibit the ac-
tivity of STAT3 in HCC [17]. Whether YC-1 could be used
to enhance the inhibition of activation of STAT3 of sorafe-
nib needs to be elucidated.
In this article, we asked whether the anti-proliferative
property of sorafenib and YC-1 in HCC tumors was syn-
ergic when administered in combination, and whether
their concomitant use played a role through the inhib-
ition of the STAT3 signaling pathway. We assessed the
combined effects of sorafenib and YC-1 on HCC cells
and xenograft models. Our results provide a rationale
for combined use of sorafenib and YC-1 in HCC.
Methods
Materials
Sorafenib was kindly provided by Bayer Pharmaceuticals.
YC-1 was obtained from Sigma-Aldrich (Saint Quentin
Fallavier, France). Anti-PARP, anti-caspase 8, anti-β-actin,
and anti-caspase 9 were obtained from Beyotime (Jiangsu,
China). Horseradish peroxidase (HRP)-labeled anti-mouse
and anti-rabbit secondary antibodies were from Santa
Cruz (Dallas, TX, USA). All other antibodies were pur-
chased from Abcam (Cambridge,TX, USA).
Cell lines and cell culture
Established human HCC cell lines, HepG2 and BEL-
7402 were from the American Type Culture Collection
(ATCC; Manassas, VA, USA). HCCLM3 was kindly pro-
vided by the Liver Cancer Institute and Zhongshan Hos-
pital (Shanghai, China) [27]. All HCC cells were maintained
in high-glucose Dulbecco’s modified Eagle medium
(DMEM) supplement with 10% fetal bovine serum (FBS),
100 U/ml penicillin and 100 μg/ml streptomycin (Life
Technologies, Cergy Pontoise, France) in a humidified at-
mosphere of 5% CO2 at 37°C. The human normal liver cell
line L02 was provided by Cancer Institute & Hospital of
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in PRMI 1640 supplement with 10% FBS, 100 U/ml penicil-
lin and 100 μg/ml streptomycin. All cell lines were immedi-
ately expanded and frozen down such that all cell lines
could be restarted every 3 months from a frozen vial of the
same batch of cells. No further authentication was done.
All cell lines were routinely tested to rule out mycoplasma
infection.
Proliferation assay
Cell proliferation assay was measured using a Cell
Counting Kit-8 (CCK-8; Dojindo Laboratories, Shanghai,
China) according to the manufacturer’s instructions.
Briefly, cells were cultured in 96-well plates at a concen-
tration of 3 ×10
3/well, incubated for 24 h, and treated
with sorafenib and/or YC-1. After 72 h treatment, CCK-
8 reagent was added to each well. The absorbance was
measured at 450 nm after 2.5 h incubation at 37°C using
an automated ELISA plate reader. Any synergistic effects
resulting from combination of the compounds were mea-
sured using the methods described by Chou and Talalay
by using Microsoft Excel software to determine the com-
bination index values (CI>1: antagonistic effect, CI=1:
additive effect, and CT<1: synergistic effect) [28].
Colony formation assay
Briefly, 6-well dishes were seeded with 1×10
3 viable cells
and allowed to grow for 24 h. The cells were then incu-
bated in the presence or absence of sorafenib, YC-1 and
their combinations for 24 h in complete medium, washed
with media, and allowed to grow in complete medium for
2 weeks. The colonies obtained were washed with PBS
and fixed in 4% paraformaldehyde for 20 min at room
temperature and then washed with PBS followed by stain-
ing with crystal violet. The colonies were counted and
compared with untreated cells. Three different independ-
ent experiments were performed.
Cell cycle analysis
HCC cells were plated in 6-well plates at 2 ×10
5 cells/
well. Following the designated treatments, cells were
harvested by trypsinization and washed with PBS and
fixed in ice-cold 75% ethanol overnight at −20°C. Fixed
cells were washed, and dissolved in RNAse and subse-
quently incubated at 37°C for 30 min. Next, cells were
stained with propidium iodide (PI) for 30 min. The
DNA content of the cells (1 ×10
4 cells per experimental
group) was determined using a BD Accuri C6 flow cyt-
ometer (BD biosciences).
Apoptosis assay
HCC cells (HepG2, BEL-7402 or HCCLM3) were seeded
in 6-well culture plates in culture medium with 2% FBS
at the concentration of 2 × 10
5 cells/well. The following
day, the cells were treated with sorafenib and/or YC-1
for a 48 h period. After treatment, cells were washed
with PBS and fixed with 4% paraformaldehyde followed
by staining with Hoechst 33258, and the apoptosis cells
were examined by immunofluorescence microscope, or
all cells including both floating and attached cell were
collected, and the apoptotic cells were detected by
Annexin V-FITC Apoptosis Detection Kit (KeyGEN Bio-
tech, Nanjing, China). The cells were stained with
Annexin V-FITC and PI according to the supplier’s in-
structions. Viable and dead cells were detected by a BD
Accuri C6 flow cytometer (BD biosciences).
Gene knockdown using small interfering RNA
SMARTpool small interfering RNAs (siRNA), including
control and STAT3 were synthesized by Shanghai Gene-
Pharma Co. (Shanghai, China). The procedure has been
described previously [29].
Western blot analysis
Cell lysate protein content was determined using a
Bicinchoninic acid (BCA) protein assay kit. Equivalent
amounts of whole cell extracts, which were based on
total protein content, were subjected to SDS-PAGE gel
and transferred to nitrocellulose membranes. The mem-
branes were blocked with 5% non-fat milk for 2 h and
then incubated with respective primary antibody over-
night at 4°C followed by the incubation with the appro-
priate HRP-conjugated secondary antibody for 1.5 h at
room temperature. Immunoreactivity was detected with
SuperSignal West Pico substrate (Thermo scientific,
Rockford, IL, USA).
SHP-1 phosphatase activity
The Rediplate 96 EnzChek
®Tyrosine Phosphatase Assay
Kit (R-22067) was used for SHP-1 activity assay (Mo-
lecular Probes, Carlsbad, CA). The SHP-1 phosphatase
activity was measured as described before [30].
Animals
Male BALB/c nu/nu mice (4–6 weeks of age) were ob-
tained from Vital River Laboratories (Beijing, China) and
housed under defined flora conditions in individually
ventilated sterile microisolator cages. All experimental
procedures using these mice were carried out in accord-
ance with protocols approved by the Animal Care and
Use Committee of Capital Medical University (Beijing,
China).
Orthotopic and ectopic HCC models
In the orthotopic model, HCCLM3 cells (5 ×10
6) were
suspended in 200 μL serum-free DMEM and matrigel
(1:1) and then injected subcutaneously into the upper
right flank region of nude mice. When the subcutaneous
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mately 4 weeks after injection), it was removed, minced
into small pieces of equal volume (2 ×2 × 2 mm
3), and
transplanted into the livers of 20 nude mice. In the ec-
topic HCC model, HepG2 cells (5 ×10
6) were suspended
in 200 μL serum-free DMEM and matrigel (1:1) and
then injected subcutaneously into the upper right flank
region of 20 nude mice. When the tumor reached a mean
size of about 100 mm
3, mice were randomized into each
experimental group according to tumor size, to start the
treatment with a similar mean size in each group. Mice
were treated with sorafenib by oral route (30 mg/kg/day),
or intraperitoneal YC-1 (10 mg/kg/day), or combination of
sorafenib and YC-1, or DMSO and polyoxyethylenated
castor oil as control every day for up to the 24th day.
Tumor size was measured with a caliper rule every 3 days.
The tumor volume was calculated as follows: TV (mm
3)=
(L×W
2)/2, where L was the longest and W the shortest ra-
dius of the tumor in millimeters. At the end of the experi-
ments, mice were euthanized, blood samples were collected
via cardiac puncture, and tumor tissues were removed for
fixation in the 4% paraformaldehyde for histologic examin-
ation and immunohistochemical staining.
Immunocytochemistry
Tissues were fixed in 4% paraformaldehyde and subse-
quently embedded in paraffin. Paraffin-embedded tissue
sections were cut into standard 6 μm sections, deparaffi-
nized in xylene and rehydrated through graded alcohol so-
lutions. Antigen retrieval was performed 10 min at 92°C in
EDTA (10 mmol/l, pH 8.0) in a water bath. Endogenous
peroxidases were inactivated by immersing the sections in
0.3% hydrogen peroxide for 12 min. The sections were
blocked with 5% goat serum for 60 min at 37°C. The slides
were incubated with primary antibodies for overnight at
4°C. Next, the slides were treated with appropriate HRP-
conjugated secondary antibody for 40 min at 37°C and then
developed with 3,3′-diaminobenzidine. Finally, the slides
were counterstained with hematoxylin and mounted. The
slides were examined with Nikon Eclipse Ti microscope
under a 200× objective.
Statistical analysis
All values are expressed as the mean ± SEM. The data
were analyzed using Student’s t test or the ANOVA test.
A P value of <0.05 was considered statistically signifi-
cant. GraphPad Prism (GraphPad Software Inc., San
Diego, California, USA) was used for these analyses.
Results
Combination of sorafenib and YC-1 inhibited HCC cell
proliferation
To determine the growth inhibition effect of combin-
ation of sorafenib and YC-1, HCC cell lines HepG2,
BEL-7402 and HCCLM3 were incubated for 72 h with
sorafenib and/or YC-1. Chemical structures of sorafenib
and YC-1 were shown in Additional file 1: Figure S1. So-
rafenib or YC-1 alone inhibited HCC cell proliferation in
a dose-dependent manner (Figure 1A). Moreover, com-
bination of sorafenib and YC-1 significantly suppressed
proliferation of HCC cells in a dose-dependent manner
(Figure 1B). To determine the long-term combination
effect of sorafenib-YC-1 treatment, cells were incubated
with sorafenib and/or YC-1 for 24 h, washed with media,
and allowed to grow in complete medium for 2 weeks.
There was lower number of colonies in the combina-
tion compared with other treatments (Figure 1C). In
addition, at the ED50 doses for both sorafenib and YC-1,
we found that CI= 0.93 in HepG2, 0.95 in BEL-7402 and
0.72 in HCCLM3 respectively, suggesting that sorafenib
and YC-1 synergistically inhibited proliferation of HCC
cells (Figure 1D). These data suggested that combination
of sorafenib and YC-1 treatment synergistically sup-
presses proliferation of HCC cells in vitro. Otherwise,
we determined the effect of the combination on prolifer-
ation of the human normal liver cell line L02. Sorafenib
(5 μM) significantly inhibited (66.9% decrease) the pro-
liferation of L02 cells (Additional file 2: Figure S2). Al-
though YC-1 (20 μM) significantly suppressed the
proliferation of L02 cells, only 12.1% decrease was ob-
served (Additional file 2: Figure S2). YC-1 could not in-
crease the toxicity of sorafenib to L02 cells (Additional
file 2: Figure S2).
The sorafenib-YC-1 combination induced cell cycle arrest
and apoptosis
Given their effects on cell proliferation, we then carried
out cell-cycle and apoptosis analysis to further cha-
racterize sorafenib-YC-1 combination effects. HepG2 cell
populations in the G0-G1 and S phases were 30.72% and
63.93% in the combination of sorafenib and YC-1 group,
while 77.42% and 17.63% in sorafenib (5 μM) group, and
45.69% and 45.12% in YC-1 group (Figure 2A). These re-
sults suggested that sorafenib-YC-1 combination signifi-
cantly induced S phase arrest compared with sorafenib
or YC-1 used alone in HepG2 cells. At 48 h, sorafenib-
YC-1 combination significantly induced apoptosis in
HepG2 cells (Figure 2B). Hoechst 33258 staining further
confirmed results above (Figure 2C). Similar results were
also found in BEL-7402 and HCCLM3 cells (data of
apoptosis assay not shown) (Additional file 3: Figure S3).
Furthermore, we determined the mechanism of cell death.
Increased activation of PARP was observed within 24 h in
all HCC cells treated with sorafenib-YC-1 combination
(Figure 2D). The apoptotic signaling pathways are gener-
ally divided into two types: the extrinsic or death receptor
pathway, which activates caspase 8, and the intrinsic or
mitochondrial pathway, which triggers the activation of
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was observed in HCC cells treated with sorafenib-YC-1
combination (Figure 2D). These data suggested that com-
bination of sorafenib and YC-1 is a potent inducer of apop-
tosis of HCC cells involved in activation of the extrinsic
apoptosis pathway.
The sorafenib-YC-1 combination suppressed STAT3
phosphorylation
We investigated the levels of phosphorylated STAT3 and
p44/42 MAPK (ERK1/2) in HepG2, BEL-7402 and
HCCLM3 cells after sorafenib and/or YC-1 treatment.
Phosphorylated STAT3 (p-STAT3) (Y705) and phos-
phorylated ERK1/2 (p-ERK1/2) were reduced at both an
early time point (4 h) and a late time point (24 h) follow-
ing sorafenib treatment in a dose-dependent manner
(Additional file 4: Figure S4). Furthermore, p-STAT3
at Y705 was also decreased at 4 h and 24 h following
YC-1 treatment in a dose-dependent manner (Additional
file 4: Figure S4). However, p-ERK1/2 was not signifi-
cantly changed at early time point following YC-1 treat-
ment. And at a late time point, p-ERK1/2 was not
Figure 1 Sorafenib-YC-1 combination synergistically inhibited proliferation of HCC cells. A, HepG2, BEL-7402 and HCCLM3 cells were incu-
bated with increasing doses of sorafenib (0–20 μmol/L) or YC-1 (0–50 μmol/L) for up to 72 h. Data were presented as percentages of cell proliferation as
determined by CCK-8 assays. B, HepG2, BEL-7402 and HCCLM3 cells were incubated with sorafenib (0–5 μmol/L) and/or YC-1 (0–20 μmol/L) for up to 72 h.
Data were presented as percentages of cell proliferation as determined by CCK-8 assays. C, HepG2, BEL-7402 and HCCLM3 cells were treated sorafenib
(2.5 μmol/L or 5 μmol/L) or YC-1 (10 μmol/L or 20 μmol/L) or in combination. The colonies were assessed. D, Synergisms of proliferation inhibition of
different cell lines were analyzed by isobologram analysis. Error bars represent the SEM of data obtained in at least three independent experiments.
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BEL-7402 only at the concentration of 50 μM YC-1
(Additional file 4: Figure S4). Moreover, p-ERK1/2 was
reduced in a dose-dependent manner at a late time point
following YC-1 treatment in HCCLM3 cells (Additional
file 4: Figure S4). Interestingly, combination of sorafenib
and YC-1 significantly inhibited the p-STAT3 (Y705)
(S727) and p-ERK1/2 compared with sorafenib or YC-1
used alone at 24 h (Figure 3A and Additional file 5:
Figure S5). Sorafenib-YC-1 combination also suppressed
the expression of cyclin D1 and survivin in all tested
HCC cell lines (Figure 3A).
Furthermore, both YC-1 and sorafenib increased SHP-
1 activity in comparison with control cells, and the com-
bination of sorafenib and YC-1 significantly increased
SHP-1 activity compared with sorafenib or YC-1 alone
in HepG2 and BEL-7402 cells (Figure 3B).
Furthermore, STAT3 siRNA was used to delete
STAT3, and the expression of p-STAT3 (Y705) and
STAT3 was significantly decreased in HepG2 and BEL-
7402 cells (Additional file 6: Figure S6A). Deletion of
STAT3 could not rescue HepG2 and BEL-7402 cells from
apoptosis. Inversely, silencing STAT3 improved the sensi-
tivity of HepG2 and BEL-7402 cells to the combination of
sorafenib and YC-1 (Additional file 6: Figure S6B).
The sorafenib-YC-1 combination inhibited tumor growth in vivo
To evaluate the role of sorafenib-YC-1 combination on
tumor growth in vivo, we examined their effects in a
HepG2 ectopic HCC model and HCCLM3 orthotopic
Figure 2 Combination of sorafenib and YC-1 induced S cell cycle arrest and apoptosis of HCC cells. HepG2 cells were treated with
combination of sorafenib (5 μmol/L) and YC-1 (10 μmol/L) or either drug for 48 h. A, Cell cycle was assayed by PI/RNAse staining. B, The treated cells
were assayed for apoptosis by annexin V/PI staining. C, Apoptosis in situ was assessed by Hoechst 33258 staining. D, Cell extracts were subjected to
western blot analysis and expression of PARP, cleaved PARP, capase 9, capsase 8 and cleaved caspase 8 was detected. Actin served as loading control.
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xenografts, and their combination exhibited an enhanced ef-
fect (Figure 4A). Similar results were observed in HCCLM3
orthotopic model (Additional file 7: Figure S7). The excised
tumors from vehicle mice, mice treated with either sorafenib
or YC-1 alone and their combination weighed approximately
2000 mg, 1500 mg, 1200 mg and 800 mg respectively, which
suggested significant effect when the mice were treated with
the combination of drugs (Figure 4B). When tumors were
treated with the combination of sorafenib and YC-1, signifi-
cant decreases of cell proliferation and increases of apoptosis
w e r eo b s e r v e db yP C N Aa n dP A R P( F i g u r e4 Ca n dA d d -
itional file 8: Figure S8). There were no apparent changes in
liver, heart, kidney, levels of serum glutamic-pyruvic trans-
aminase (GOT) and glutamic oxalacetic transaminase (GST)
and body weight in the mice (Additional file 9: Figure S9A,
B and D). But the mice treated with sorafenib alone showed
significant decreased spleen volume (0.0702±0.003247 g)
compared with control group (0.1050±0.007266 g), YC-1
group (0.0992±0.000860 g) or sorafenib+ YC-1 group
(0.08660±0.003530 g) (Additional file 9: Figure S9C). These
data implied that the sorafenib-YC-1 may be a potential
therapeutic combination for treating HCC, and relatively
nontoxic to the animals.
Sorafenib and YC-1 combination inhibited the STAT3 signaling
associated proteins and tumor angiogenesis in vivo
Furthermore, treatment with the sorafenib and YC-1
combination led to a significant reduction in p-STAT3,
cyclin D1, and survivin compared with sorafenib or YC-1
used alone (Figure 4D and Additional file 8: Figure S8).
Endothelial-specific antigen CD31 and VEGF levels were
also significantly lower in sorafenib-YC-1 combination-
treated tumor xenografts (Figure 4E and Additional file 8:
Figure S8).
Discussion
HCC typically arises on the basis of cirrhosis and re-
sponds poorly to conventional cytotoxic chemotherapy
[31]. This has led to a search for novel approaches for
molecular targeted therapy. The RAF/MEK/ERK cascade
is one of the principal RAS-regulated pathways. Raf ex-
pression has been reported to be increased in human
HCC, and sorafenib was synthesized to molecularly tar-
get RAF in this vital pathway and has been shown to
have anti-tumor activity against renal cell cancer and
HCC. However, recent researches have shown that
STAT3 is a vital target of sorafenib and its effect is not
correlated to the repression to Raf-1 kinase [22,23]. In
addition, sorafenib causes multiple toxicities and a large
percent of patients need to be treated with a reduced
dose or stop taking the drug for this reason [32]. So we
wanted to search for new agents that could be combined
with sorafenib to reduce the dose dosage of sorafenib
and enhance its HCC growth inhibition through en-
hanced suppressing STAT3 activity. In the present study,
we showed not only the combined anti-tumor effects of
low-dose sorafenib and YC-1 therapy against HCC both
Figure 3 Combination of sorafenib and YC-1 suppressed the activity of STAT3 and expression of its associated protein. HepG2, BEL-7402
and HCCLM3 cells were incubated with sorafenib (5 μmol/L) in combination with YC-1 (10 μmol/L or 20 μmol/L) or either drug alone for 24 h. A. Cell
extracts were subjected to western blot analysis and expression of p-STAT3 (Y705), STAT3, cyclin D1 and survivin was assessed. Actin served as loading
control. B. SHP-1 activity was measured in HepG2 and BEL-7402 cells.
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through which YC-1 sensitized HCC cells to sorafenib.
Our results indicated that the sorafenib-YC-1 combin-
ation possesses potential as a promising therapeutic
agent against HCC.
Sorafenib is the first and only molecular targeted ther-
apy approved for HCC and could inhibit proliferation of
HCC cells by inducing apoptosis [33]. However, the poor
response rate renders the drug less than satisfactory. In
this study, YC-1 was used to enhance its inhibition. We
found that sorafenib-YC-1 combination synergistically
inhibited proliferation of HCC cells. Apoptosis and cell
cycle analysis was further used to elucidate the mechan-
ism involved in the synergistical effect of sorafenib and
YC-1. Combination of sorafenib and YC-1 induced more
apoptosis (23.99%) compared with sorafenib (16.77%) or
YC-1 (5.1%) alone. Apoptosis rate was limited, which
may not explain synergistical effect of sorafenib and YC-
1. Our data demonstrated that YC-1 significantly in-
duced S cell cycle arrest compared with the vehicle, and
sorafenib increased the S cell cycle arrest of YC-1 in all
HCC cells. Interestingly, Eun-Jin Yeo et al. (2006) sug-
gested that YC-1 induced S cell cycle arrest and apop-
tosis by activating checkpoint kinases in Hep3B cells
[18]. However, Wang SW et al. (2005) showed that YC-1
exhibited an anti-proliferative effect and arrested the cell
cycle in G0-G1 in human HCC cells [19]. The reasons
may be contributed to the different doses of YC-1 in the
studies. Our results were consistent with Eun-jin Yeo el
al. and further suggested that sorafenib could enhance
the S cell cycle arrest of YC-1. Our data indicated that
apoptosis and S cell cycle induced by sorafenib-YC-1
combination may be the mechanism of their synergisti-
cal inhibition of proliferation in human HCC cells.
Figure 4 Combination of sorafenib and YC-1 inhibited growth of HepG2 tumor xenografts. HepG2 cells were injected subcutaneously into
the upper right flank region of nude mice. When the tumor reached a mean size 100 mm
3, mice were treated with combination of sorafenib
(30 mg/kg/day) and YC-1 (10 mg/kg/day) or either drug alone every day for up to the 24th day. A, Tumor size was measured with a caliper rule
every 3 days. Data were presented as the mean tumor volumes of mice in both treatment and vehicle groups on the days post-treatment. B,
Average tumor weight was shown at the end of the experiments. C and D, Tumor sections were stained for PCNA, PAPR, p-STAT3, cyclin D1
and survivin. Representive images of the immunohistochemistry assay were shown (200×). E, Tumor sections were stained for CD31 and VEGF.
Representive images of the immunohistochemistry assay were shown (200×). Error bars represent the SEM of tumor weight. P value <0.05
was considered statistically significant; ***p< 0.001, **p<0.01, *p<0.05.
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tumor progression because it can be triggered by cyto-
kines and growth factors such EGFR, FGFR and PDGF
through tyrosine phosphorylation [34]. Many STAT3-
related genes such as cyclin D1 and survivin also play
roles in cell proliferation and survival signaling [35].
Constitutive activation of STAT3 is observed in 72.4% of
human HCC and in a wide variety of other cancer types
not in normal cells [36], which represents an attractive
molecular target. In HCC, STAT3 frequently correlates
with the constitutive upregulation of Ras implicated in
HCC progression [37]. The anti-tumor activity of sorafe-
nib does not necessarily correlate with the inhibition of
ERK phosphorylation in HCC cells [25]. Previous studies
also reported that STAT3 was the key factor in the
mechanism of sorafenib resistance, and STAT3 rather
than Raf-1 was critical in the anti-cancer effect of sorafe-
nib [30]. Our studies showed that YC-1 or sorafenib
alone suppressed the activity of STAT3 in a time- and
dose-dependent manner. Furthermore, combination of
sorafenib and YC-1 significantly inhibited the p-STAT3
(Y705) (S727) compared with sorafenib or YC-1 alone.
Meantime, YC-1 did not inhibit the activity of p-ERK1/2
or only performed at a high dose (50 μM), which may be
not significant in the clinic. However, combination of
sorafenib and YC-1 significantly suppressed p-ERK1/2 in
all tested HCC cell lines, whose mechanism needed to
be determined in the future. Sorafenib suppresses the
activity of STAT3 through enhancing SHP-1 activity
[30]. Our results showed that combination of sorafenib
and YC-1 may suppress the expression of p-STAT3
through inhibiting the of SHP-1 activity. And sorafenb-
YC-1 combination also significantly suppressed the expres-
sion of cyclin D1 and survivin. These results indicated that
YC-1 may be used to enhance the inhibition of STAT3
activity of sorafenib, and further suppress the HCC growth
(Figure 5).
We examined the in vivo effect of sorafenib-YC-1
combination in HCC xenografts in nude mice. We dem-
onstrated that combination of sorafenib (30 mg/kg/d)
and YC-1 (10 mg/kg/d) could significantly suppress the
growth of HCC tumor when compared with either drug
alone. Of note, apparent toxicity was not observed in
heart, lung, liver and kidney. But shrank spleen were
found in the sorafenib group and the mechanism in-
volved should be further elucidated to assure the safe
use. Also, the treatment allowed the mice to maintain
normal weight gain and levels of serum GOP and GPT.
Our studies showed that combination of sorafenib and
YC-1 could be safe to be used in vivo, which provided
the preliminary basis for potential use for HCC patients
in the future. Furthermore, combination of sorafenib
and YC-1 also suppressed the expression of VEGF and
microvessel density (CD31) in HCC tumor compared
with either drug alone. VEGF is the most potent angio-
genic factor and plays a key role in tumor associated
angiogenesis and hyper-permeability [38]. Studies have
shown that VEGF is frequently expressed in HCC [29].
Our data suggested that sorafenib-YC-1 combination to
inhibit VEGF and CD31 expression may be another mo-
lecular mechanism to prevent HCC growth. Moreover,
Liang et al. recently showed that anti-angiogenic activity
of sorafenib could be responsible for the activation of re-
sistance mechanisms, sustained sorafenib treatment led
to increased intratuour hypoxia and induction of HIF-1α
expression that mediated cell survival, and the use of
HIF-1α inhibitors (EF24) abolished drug resistance [39].
YC-1 is also a HIF-1α inhibitor, so YC-1 may play a
assisting role in anti-tumor of sorafenib through the
mechanism above, which confirms us that sorafenib-YC-
1 combination could be potential for use for HCC pa-
tients in near future.
Conclusions
Our results revealed that YC-1 has a synergistic effect
with sorafenib on HCC through inhibition of STAT3 ac-
tivity and that the STAT3 signaling pathway may be a
suitable target for the development of anti-HCC targeted
agents.
Figure 5 Association of between combination of sorafenib and
YC-1 and STAT3 cascade.
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Additional 1: Figure S1. Chemical structures of sorafenib and YC-1
were shown.
Additional 2: Figure S2. The effect of sorafenib and YC-1 on the prolif-
eration of L02 cells. L02 cells were incubated with sorafenib (0–5 μmol/L)
and/or YC-1 (0–20 μmol/L) for up to 72 h. Data were presented as per-
centages of cell proliferation as determined by CCK-8 assays.
Additional 3: Figure S3. Combination of sorafenib and YC-1 induced S
cell cycle arrest and apoptosis of HCC cells. BEL-7402 and HCCLM3 cells
were treated with combination of sorafenib (5 μmol/L) and YC-1
(20 μmol/L) or either drug for 48 h. A, Cell cycle was assayed by PI/RNAse
staining in BEL-7402 and HCCLM3 cells. B, The treated cells were assayed for
apoptosis by annexin V/PI staining in BEL-7402 cells. C, Apoptosis in situ was
assessed by Hoechst 33258 staining in BEL-7402 and HCCLM3 cells.
Additional 4: Figure S4. Sorafenib and YC-1 affected STAT3 and ERK1/2
pathways. HepG2, BEL-7402 and HCCLM3 cells were treated with increasing
doses of sorafenib (0–20 μmol/L) or YC-1 (0–50 μm o l / L )f o ru pt o4ho r2 4h .
Cell extracts were subjected to western blot analysis and expression of p-ERK1/2,
ERK2, p-STAT3 (Y705), STAT3 was detected. Actin served as loading control.
Additional 5: Figure S5. Combination of sorafenib and YC-1 sup-
pressed the activity of STAT3 (S727). HepG2, BEL-7402 and HCCLM3 cells
were incubated with sorafenib (5 μmol/L) in combination with YC-1
(10 μmol/L or 20 μmol/L) or either drug alone for 24 h. Cell extracts were
subjected to western blot analysis and expression of p-STAT3 (S727) and
STAT3 was assessed. Actin served as loading control.
Additional 6: Figure S6. Down-regulation of STAT3 sensitized HCC cells
to combination of sorafenib and YC-1. A, siRNA was used to silence the
expression of STAT3 in HepG2 and BEL-7402 cells. The expression of
p-STAT3 (Y705) and STAT3 was assessed by western blot. Actin served as
loading control. B, After HepG2 and BEL-7402 cells were transferred with
STAT3 siRNA, sorafenib and YC-1 were added to treat the HepG2 and
BEL-7402 cells. Apoptosis cells were analyzed by annexin V/PI staining.
Additional 7: Figure S7. Combination of sorafenib and YC-1 inhibited
growth of orthotopic HCCLM3 tumor. HCCLM3 cells were injected sub-
cutaneously into the upper right flank region of nude mice. When the
subcutaneous tumor reached approximately 1 cm in length, it was
minced into small pieces of equal volume, and transplanted into the
livers of 20 nude mice. When the tumor reached a mean size of about
100 mm
3, mice were treated with combination of sorafenib (30 mg/kg/
day) and YC-1 (10 mg/kg/day) or either drug alone every day for up to
the 24th day. Representative image of tumor volume was displayed.
Additional 8: Figure S8. The expression of PCNA, PARP, p-STAT3 (Y705),
cyclin D1, survivin, CD31 and VEGF was quantified by Image-Pro Plus.
Additional 9: Figure S9. Toxicity of sorafenib and/or YC-1 on nude
mice bearing with tumor. HepG2 cells were injected subcutaneously into
the upper right flank region of nude mice. When the tumor reached a
mean size of about 100 mm
3, mice were treated with combination of
sorafenib (30 mg/kg/day) and YC-1 (10 mg/kg/day) or either drug alone
every day for up to the 24th day. A, Mice weight was measured with a
scale every 3 days. B, The levels of serum GOP and GPT were shown at
the end of the experiments. Error bars represent the SEM of concentration
of GOP and GPT. C, Spleen weight was measured at the end of the
experiments. D, Heart, lung, liver and kidney sections were stained with
haematoxylin and eosin (HE). Representive images were shown (200×).
ns, no significance.
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